Cambridge, UK, 10 Jan 2023: o2h technology, a business vertical of the o2h group, is excited to announce the launch of the o2h tech kickstarter competition exclusively for seed stage life science, greentech and tech/AI companies to help them boost their MVP, web, mobile app design & development activities.
o2h technology understands that it has always been a challenge for seed stage companies to design, build and scale their application/products due to various barriers including the high cost of hiring quality developers, access to CTO-level technology expertise, and access to expert…
Announcing The Herts Healthcare Accelerator programme at the University of Hertfordshire - designed to support the development of healthcare, biotech and medtech innovations, including new potential products, services, or allied technologies.
Successful applicants will access a tailored package of support worth around £13,500 per company from a range of industry and academic experts to help them deliver their proposed idea. For more information and to express interest follow the link below. The closing date for expressing an interest is 31st January.
https://www.herts.ac.uk/enterprise-zone/…
AMSBIO reports how the Faculty of Biological Sciences at the University of Leeds (UK) is using their specialty reagents for the production, visualization, and analysis of glycans and to investigate their interactions which are instrumental to the advance of glycobiology.
Glycobiology is vital for many biological processes — from fertilization to inflammation — helping unlock information about interactions between carbohydrates and proteins and providing the mechanism by which many viruses and bacteria latch on to healthy cells. Leading research groups around the world are using glycobiology…
Astrea Bioseparations (“Astrea Bio”), a leading provider of high-quality bioseparation and purification technologies, announced today the acquisition of Delta Precision Ltd. ("Delta Precision"), a premier manufacturer of advanced chromatography columns for the biotechnology and pharmaceutical industries.
This strategic acquisition, which follows a long-standing relationship of almost a decade, will allow Astrea Bio to expand its product offering to include a full range of high-performance chromatography columns for biomanufacturing, complementing and strengthening the company's…
60,000 sq ft flagship office and laboratory building now fully let
Cambridge, 9th January 2023: Leading regional property investor and developer Howard Group is delighted to welcome Chimeris UK Limited to Unity Campus. The biotech company has secured Suite 5 (8,000 sq ft), the last available space within ‘The Works’ building, thereby completing the leasing of phase 1 at Unity Campus.
As part of the letting, Howard Group is fitting out Suite 5 as CL2 wet laboratory space. McManniman has been appointed to deliver the…
Cambridge, UK, 05 January 2023: PhoreMost Ltd., has triggered a milestone payment in its multi-project target discovery collaboration with Boehringer Ingelheim. This was achieved by identifying and validating novel targets supporting Boehringer Ingelheim’s ambition to develop first-in-class therapies, to transform patients’ lives.
PhoreMost and Boehringer Ingelheim entered a multi-project collaboration back in January 20201, with PhoreMost deploying its in-house expertise and next-generation phenotypic screening platform, SITESEEKER®, towards disease-relevant pathways selected by Boehringer…
Marks & Clerk are proud to present The IP Driven Start-up e-book, which is released today!
Authored by Robert Lind, leading intellectual property firm Marks & Clerk brings you a pithy summary of the issues facing the IP driven start up and how to deal with these.
This book emphasises what the founders need to put in place at the outset to secure their IP assets and ensure that maximum value is obtained at the point of exit. It also considers the steps that need to be taken to manage growth and avoid IP assets slipping through the net.
To request your free download of the book, please…
We’re helping NeoVac fast-track its revolutionary lipid nanoparticle technology to clinical trials, to make RNA vaccines and therapies more transportable and able to tackle multiple pathogen variants while having fewer side effects compared with existing licensed vaccines.
Through this partnership, we will enable and accelerate the clinical testing of NeoVac’s lipid nanoparticle (LNP) drug delivery technology. We will develop scalable processes and manufacture clinical-grade batches of RNA-LNP product, focusing initially on doses to tackle new and emergent variants of COVID-19, before…
Cambridge, UK, 3rd January 2023, Astex Pharmaceuticals, UK, congratulates Harren Jhoti, PhD, FRS, FMedSci, its co-founder, President and CEO on being honoured in the 2023 King’s New Year Honours list. Dr Jhoti has been made an Officer of the Order of the British Empire (OBE) for services to Cancer Research and Drug Discovery.
Dr. Jhoti co-founded Astex in 1999 to pioneer the development of fragment-based drug discovery (FBDD), a ground-breaking new approach now widely used in the pharmaceutical industry, and which the company has used to help discover two new marketed cancer…